Andrew Simon

Andrew Simon

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab In RELATIVITY-047, Opdualag more than doubled median progression-free survival compared to nivolumab monotherapy Bristol Myers Squibb( NYSE BMY) moment blazoned that the…

AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Congress

–Results will be presented from the Phase 3 M15-736 trial, a randomized, double-blind, double-dummy, active-controlled study, evaluating the continuous subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) in people with advanced Parkinson’s disease–Data will also be presented on real-world efficacy of BOTOX® (onabotulinumtoxinA) for…